WO2019130277A1 - Formulations pharmaceutiques d'azilsartan médoxomil - Google Patents

Formulations pharmaceutiques d'azilsartan médoxomil Download PDF

Info

Publication number
WO2019130277A1
WO2019130277A1 PCT/IB2018/060716 IB2018060716W WO2019130277A1 WO 2019130277 A1 WO2019130277 A1 WO 2019130277A1 IB 2018060716 W IB2018060716 W IB 2018060716W WO 2019130277 A1 WO2019130277 A1 WO 2019130277A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
composition according
granulating
pharmaceutical composition
solvent
Prior art date
Application number
PCT/IB2018/060716
Other languages
English (en)
Inventor
Makarand Krishnakumar Avachat
Nikhil Prabhakar Malewar
Anirudha Bhagirath Kute
Sandeep Dhondibhau POTE
Cheriyan AJI
Sagar Baburao PATIL
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of WO2019130277A1 publication Critical patent/WO2019130277A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant de l'azilsartan médoxomil ou un sel pharmaceutiquement acceptable de celui-ci et au moins un excipient pharmaceutiquement acceptable, lesdites compositions obtenant simultanément une stabilité souhaitée ainsi que des caractéristiques de dissolution.
PCT/IB2018/060716 2017-12-30 2018-12-29 Formulations pharmaceutiques d'azilsartan médoxomil WO2019130277A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721047406 2017-12-30
IN201721047406A IN201721047406A (fr) 2017-12-30 2018-12-29

Publications (1)

Publication Number Publication Date
WO2019130277A1 true WO2019130277A1 (fr) 2019-07-04

Family

ID=65278423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/060716 WO2019130277A1 (fr) 2017-12-30 2018-12-29 Formulations pharmaceutiques d'azilsartan médoxomil

Country Status (2)

Country Link
IN (1) IN201721047406A (fr)
WO (1) WO2019130277A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022182778A1 (fr) * 2021-02-24 2022-09-01 Nostrum Pharmaceuticals, Llc Emballages pharmaceutiques et procédés de réduction de la formation de n-nitrosodiméthylamine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123592A1 (fr) * 2020-12-08 2022-06-16 Alkem Laboratories Ltd Composition pharmaceutique stable d'azilsartan médoxomil ou de sel pharmaceutiquement acceptable et procédés de préparation de celle-ci

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583141A (en) 1991-06-27 1996-12-10 Takeda Chemical Industries, Ltd. Heterocyclic compounds and their use as angiotensin antagonists
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20100016382A1 (en) 2006-08-10 2010-01-21 Takeda Pharmaceutical Company Limited Pharmaceutical composition
US20110201658A1 (en) 2006-02-27 2011-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical package
US20120100093A1 (en) 2006-09-25 2012-04-26 Takeda Pharmaceutical Company Limited Medicinal package
WO2014102628A1 (fr) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Composition pharmaceutique stable comprenant de l'azilsartan médoxomil
CN103096878B (zh) * 2011-05-23 2015-06-17 江苏恒瑞医药股份有限公司 包含苯并咪唑衍生物的固体药物组合物
US9066936B2 (en) 2007-03-28 2015-06-30 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
US20160008328A1 (en) * 2014-07-11 2016-01-14 Cadila Healthcare Limited Stable Pharmaceutical Package Comprising Azilsartan Medoxomil
CN105456210A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种高生物利用度的阿齐沙坦组合物
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583141A (en) 1991-06-27 1996-12-10 Takeda Chemical Industries, Ltd. Heterocyclic compounds and their use as angiotensin antagonists
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7572920B2 (en) 2004-02-25 2009-08-11 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as a II receptor antagonist
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20110201658A1 (en) 2006-02-27 2011-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical package
US20100016382A1 (en) 2006-08-10 2010-01-21 Takeda Pharmaceutical Company Limited Pharmaceutical composition
US20120100093A1 (en) 2006-09-25 2012-04-26 Takeda Pharmaceutical Company Limited Medicinal package
US9066936B2 (en) 2007-03-28 2015-06-30 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
CN103096878B (zh) * 2011-05-23 2015-06-17 江苏恒瑞医药股份有限公司 包含苯并咪唑衍生物的固体药物组合物
WO2014102628A1 (fr) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Composition pharmaceutique stable comprenant de l'azilsartan médoxomil
US20160008328A1 (en) * 2014-07-11 2016-01-14 Cadila Healthcare Limited Stable Pharmaceutical Package Comprising Azilsartan Medoxomil
CN105456210A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种高生物利用度的阿齐沙坦组合物
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROWN, M J; HAYCOCK, S, DRUGS, vol. 59, no. 2, 2000, pages 1 - 12
FAGARD, R. H., AM. J. GERIATRIC CARDIOLOGY, vol. 11, no. 1, 2002, pages 23 - 28

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022182778A1 (fr) * 2021-02-24 2022-09-01 Nostrum Pharmaceuticals, Llc Emballages pharmaceutiques et procédés de réduction de la formation de n-nitrosodiméthylamine

Also Published As

Publication number Publication date
IN201721047406A (fr) 2020-06-19

Similar Documents

Publication Publication Date Title
RU2201754C2 (ru) Фармацевтический состав, способ его получения, способ лечения психотических состояний и гиперактивности
AU2009349125B2 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
KR102241643B1 (ko) 비정질 톨밥탄을 함유하는 경구 투여 현탁제
JPH10194969A (ja) 錠剤組成物
EP2252273B1 (fr) Composition pharmaceutique solide incluant un antagoniste non peptidique du récepteur de l'angiotensine ii et un diurétique
US20150238616A1 (en) Solid preparation comprising enteric solid dispersion
WO2006070248A1 (fr) Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine
JP7231255B2 (ja) 改善されたブロモクリプチン製剤
CA2801020A1 (fr) Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
MX2014007700A (es) Nueva combinacion.
WO2020239986A1 (fr) Composition de comprimé pharmaceutique comprenant de l'edoxaban
AU2013365715B2 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
WO2019130277A1 (fr) Formulations pharmaceutiques d'azilsartan médoxomil
CA2628955A1 (fr) Compositions de ramipril stabilise en combinaison avec un autre agent actif
JP2015061828A (ja) 口腔内崩壊錠及びその製造方法
EP2538924B1 (fr) Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation
US6333361B1 (en) Pharmaceutical composition containing zafirlukast
US20160008328A1 (en) Stable Pharmaceutical Package Comprising Azilsartan Medoxomil
ES2663721T3 (es) Formulaciones de olmesartán
JP2015091830A (ja) 有機化合物のガレヌス製剤
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
JP2011136908A (ja) アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
EP4079297A1 (fr) Formulation pharmaceutique comprenant de la cibenzoline ou un sel de celle-ci
EP2392318A1 (fr) Composition pharmaceutique à libération prolongée du losartan
WO2017093890A1 (fr) Formulation de comprimé à base de clobazam et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18842851

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18842851

Country of ref document: EP

Kind code of ref document: A1